SCHEMBL1092155

SCHEMBL1092155

CC(C)[Si](OC1CCN(N2CCC(Cc3c(Cl)cc(-c4ccc(C(=O)O)cc4)cc3Cl)C2=O)CC1)(C(C)C)C(C)C

nearest known ligand 0.33

Predicted protein targets (top 19)

geneUniProtsupporting neighboursconfidence
SRD5A2 P31213 3/20 0.33
HRH1 P35367 2/20 0.33
CCR3 P51677 2/20 0.33
KCNH2 Q12809 2/20 0.33
CYP2C9 P11712 1/20 0.32
EPHX2 P34913 1/20 0.32
CYP2J2 P51589 1/20 0.32
CMA1 P23946 3/20 0.32
SSTR5 P35346 1/20 0.32
NR1H4 Q96RI1 1/20 0.31
PDE4A P27815 2/20 0.31
PDE4B Q07343 2/20 0.31
PDE4C Q08493 2/20 0.31
PDE4D Q08499 2/20 0.31
ADRB3 P13945 1/20 0.31
ROCK2 O75116 1/20 0.31
RXRA P19793 2/20 0.31
RXRB P28702 2/20 0.31
CHEK1 O14757 1/20 0.30

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL1092153 1.00 SRD5A2 (0.33) SRD5A2HRH1CCR3KCNH2CYP2C9
SCHEMBL1092145 0.92 CHKA (0.34) PDE4APDE4BPDE4CPDE4D
SCHEMBL1092143 0.92 CHKA (0.34) PDE4APDE4BPDE4CPDE4D
SCHEMBL1094079 0.91 ROCK2 (0.35) SRD5A2HRH1CCR3KCNH2CYP2C9
SCHEMBL1092227 0.91 ROCK2 (0.35) SRD5A2HRH1CCR3KCNH2CYP2C9
SCHEMBL1092804 0.88 ALDH1A1 (0.41) HRH1
SCHEMBL1092806 0.88 ALDH1A1 (0.41) HRH1
SCHEMBL1093126 0.87 FASN (0.37) HRH1CCR3PDE4APDE4BPDE4C
SCHEMBL1093124 0.87 FASN (0.37) HRH1CCR3PDE4APDE4BPDE4C
SCHEMBL208539 0.86 SRD5A2 (0.35) SRD5A2CMA1SSTR5NR1H4

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-8153807-B2 Inhibitors of 11-beta-hydroxysteroid dehydrogenase 1 ELI LILLY AND COMPANY (US) 2012-04-10 US disclosed
EP-2021336-B1 INHIBITORS OF 11-BETA-HYDROXYSTEROID DEHYDROGENASE 1 LILLY CO ELI (US) 2010-06-30 EP disclosed
US-20090111809-A1 INHIBITORS OF 11-BETA-HYDROXYSTEROID DEHYDROGENASE 1 BUSH JULIE KAY 2009-04-30 US disclosed
EP-2021336-A2 INHIBITORS OF 11-BETA-HYDROXYSTEROID DEHYDROGENASE 1 ELI LILLY AND COMPANY (US) 2009-02-11 EP disclosed
WO-2007127688-A2 INHIBITORS OF 11-BETA-HYDROXYSTEROID DEHYDROGENASE 1 ELI LILLY AND COMPANY (US) 2007-11-08 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20090111809-A1 INHIBITORS OF 11-BETA-HYDROXYSTEROID DEHYDROGENASE 1 HSD11B1, HSD3B1, HSD11B2 SRD5A2 23/4885HRH1 1935/4885CCR3 2866/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.